ABT-related mortality based on deaths reported to three major hemovigilance systems
| Country . | Type of surveillance system . | Reporting period . | ABT-related mortality* . |
|---|---|---|---|
| France | Hemovigilance/mandatory reporting2 | 1994-1999 | 5.6 |
| United Kingdom | Hemovigilance/voluntary reporting3 | 1996-2004 | 3.5 |
| United States | Passive reporting of deaths1 | 2007 | 2.3 |
| Country . | Type of surveillance system . | Reporting period . | ABT-related mortality* . |
|---|---|---|---|
| France | Hemovigilance/mandatory reporting2 | 1994-1999 | 5.6 |
| United Kingdom | Hemovigilance/voluntary reporting3 | 1996-2004 | 3.5 |
| United States | Passive reporting of deaths1 | 2007 | 2.3 |
Number of deaths per million components transfused (in France2 or the United States1 ) or issued for transfusion (in the United Kingdom3 ).